Вход на сайт

(Забыли свой пароль?)



Devaluation against patients

How to change the price of imported medicines due to rising exchange rates and whether Russian developments that can replace foreign drugs , understood the science department "Gazety.Ru" .

Where are imported medicines

To understand what will happen to the prices of medicines in the conditions when the dollar rises , it is necessary to present the way in which drugs are brought to market . We buy tablets and capsules in the pharmacy , and the pharmacy shelf , they fall through the distribution companies that buy drugs from manufacturers. In the role of producers increasingly advocated by international pharmaceutical companies have their representatives in Russia , sometimes Russian manufacturers producing generic drugs - drugs reproduced under the generic name , and very rarely - innovative drugs .

Although generic contain the same active ingredient as the original drug , and they are tested for therapeutic equivalence of efficacy in most cases lower than those of the original drugs.

Thus, the main market participants : producers, distributors and pharmacies. Procurement for themselves there are two ways . Every year the Ministry of Health carries out through distributors government procurement of certain drugs in the first place on the list of vital and essential drugs ( VED ) . While the purchase prices are determined through tenders . But the company's distributors work with producers and myself, and this part of the purchase price , of course, no one regulates. And in different pharmacies prices for the same drug can vary considerably , as pharmacies, as any company engaged in the retail sale, set the trading margin . And there is a national network of pharmacies as a fixed mark-up , and much more numerous private pharmacy chains .

The dollar and the euro are rising and prices of medicines ?

With the increase in the dollar would naturally expect higher prices for imported drugs , and experts confirm this.

They expect growth in retail prices by 15% as a minimum.

But since there are pharmaceutical warehouses supply of drugs , the rise in prices will occur gradually over a period of 3-4 months .

Changes do not have to touch the drugs listed VED as they are fixed margins . In 2014, this list contains the same number as in 2012 (567 names of drugs).

However , experts say it may be an additional problem for the manufacturer . Since the margin is not revised , if the producers will find it unprofitable supply of drugs , they can stop them .
" The devaluation of the ruble led to higher prices for drugs that are not included in the VED - said " Gazeta.ru " experts of the Russian branch of the international pharmaceutical company " Novartis " . - However, it will strike for more patients to pay for drugs . "

Russian pharmaceutical market changes began to occur and to increase the exchange rate . As told "Gazeta.ru" Orestes Ibragimov , CEO of the Russian pharmaceutical company OOO " Izvarino Pharma ", " last year has shown that the Russian pharmaceutical market ( in the absolute number of packages of drugs ) observed a slight tendency to reduce , change in exchange rates will accelerate this process .

People will be more selective about what to buy or not to buy the drug , especially if it is an expensive drug , and often decide not to buy, due to the fact that they can not afford. "

At the same time, the volume of public procurement and purchase prices for them, according to experts, should not change this year , despite fluctuations in the exchange rate, since the trades have already passed , the agreement signed with pharmaceutical companies , the prices are fixed. And next year is likely to change the budget for public procurement .

It also reaffirmed " the Newspaper " and experts "Novartis" :

Within the framework of public procurement prices probably will not rise due sfederalnym law of contractual procurement system ( FL -44 ), which is likely to lead to fixing auction prices in rubles at the level of last year. "
In the current environment is natural to expect that the Russian market will turn to the Russian manufacturer . Although a ban on the purchase of imported drugs , like prohibition of purchases of imported medical equipment, which is contained in a bill introduced by the Ministry of Industry is obviously impossible , the share of domestic pharmaceutical market can change. Although experts do not expect a significant increase it .

"This trend is very weak, - said " Gazeta.ru " Orestes Ibragimov . - Judging by the pharmaceutical market analyst reports , changing this ratio is very slightly. Though in the case of expensive drugs procured by the state , the changes are more visible to a greater extent due to the program Minpromtorga Strategy pharmaceutical development until 2020. The program really works , now have domestic substitutes drugs that effectively replace imports , and the government has already acquired such drugs . It is generic , or, more correctly , generics . "

As the experts say , " Novartis ", " Major trends in public procurement of drugs - dzhenerikozameschenie . While domestic generics receive a 15 percent price preference in tenders . "

As for the original , innovative domestic pharmaceutical products , their share in the total volume of pharmaceutical development and, accordingly , the market share so far is negligible . Experts estimate it is no more than 1 %.
This before , "Gazeta.ru" said Dr. Alexander Chemistry Gabibov expert scientific and technical council Minpromtorga "Now Russian innovation is sufficiently small. The Russian market is moving towards the creation of generic drugs . And maybe this is the right path of growth of the pharmaceutical industry , because we need to create a database . "

Although attempts to increase the share of domestic pharmaceutical development undertaken . " The program is supporting the development of local drugs also realized Minpromtorgom - says Orest Ibragimov . - A number of companies carries out its development in this direction , such as the company " KhimRar " is a Russian manufacturer, has a lot of development of innovative drugs . Our company " Izvarino Pharma" is also moving in this direction , we develop innovative medicines in collaboration with "Rusnano" .

Enumerating the Russian innovations , Alexander Gabibov mentioned antibacterial and antiviral drugs that are created in the Institute. Gamal , neurotropic drugs that are created in the Institute of Pharmacology RAMS , and the development of drugs based on recombinant proteins. Add a drug for the treatment of HIV infection , created at the Research Institute of Chemical Diversity " KhimRar ", which is undergoing clinical trials .

Yet, experts do not expect that the share of Russian innovative products on the market will grow substantially . As stressed by Orest Ibragimov, "because the pharmaceutical market differs from other certain conservatism .
And also because it makes no sense for pharmaceutical companies to implement innovative developments in one country . We can only talk about pharmaceutical developments with interest for the global market .
These are the realities of globalization. Companies who undertake innovations , globalization should have ambitions of these developments on the world market . Such companies in the Russian units . "

Source : www.recipe.ru


Would you like to leave your comment? Please Login to your account to leave comments. Don't have an account? You can create a free account now.